Biora Therapeutics (Biora Therapeutics) Capex-to-Revenue : 0.03 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biora Therapeutics's Capital Expenditure for the three months ended in Mar. 2024 was $-0.02 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.54 Mil.

Hence, Biora Therapeutics's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.03.

Biora Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Biora Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Capex-to-Revenue Chart

Biora Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

0.03

23.90

0.69

2.60

25.75

Biora Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial															8.00	10.00	-	-	0.03

Competitive Comparison of Biora Therapeutics's Capex-to-Revenue

For the Biotechnology subindustry, Biora Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biora Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's Capex-to-Revenue falls into.

Biora Therapeutics Capex-to-Revenue Calculation

Biora Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.103)	/	0.004
	=	25.75

Biora Therapeutics's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.015)	/	0.542
	=	0.03

Biora Therapeutics (NAS:BIOR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Biora Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics (Biora Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

4ZU0:Germany 4ZU0:Germany

Address

4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122

Website

https://www.bioratherapeutics.com

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Executives

Athyrium Opportunities Iii Co-invest 1 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty	director, officer: Chief Executive Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe	director	C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp	10 percent owner	605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi	officer: Chief Compliance Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry	officer: Chief Operating Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter	director	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp	10 percent owner	505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli	director, officer: Chairman & CEO	3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper	officer: Chief Scientific Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104